Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis-Reference-Cited by-同舟云学术

Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis

Published:2018-05-18 Issue:6 Volume:11 Page:641-650
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Sridharan Kannan¹^ORCID,Sivaramakrishnan Gowri²

Affiliation:

1. Department of Pharmacology and Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain

2. School of Oral Health, College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, Fiji islands

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2018.1473760

Reference52 articles.

1. IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA

2. Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin

3. Iron overload thalassemic cardiomyopathy: Iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity

4. Iron-Chelating Therapy for Transfusional Iron Overload

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel meroterpene-like compounds inhibit ferroptosis through Fe2+ chelation;The International Journal of Biochemistry & Cell Biology;2024-08

2. Ferroptosis inhibitors: past, present and future;Frontiers in Pharmacology;2024-05-23

3. Fighting age-related orthopedic diseases: focusing on ferroptosis;Bone Research;2023-03-01

4. Serious Blood Disorders: A Focus on Sickle Cell Disease and Hemophilia;Palliative Care in Hematologic Malignancies and Serious Blood Disorders;2023

5. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis;Journal of International Medical Research;2022-12